A French biotechnology company said that its cancer vaccine was effective in decreasing the risk of death for people with some lung cancers by 41%.
Category
🗞
NewsTranscript
00:00 [Music]
00:13 We have a biomarker that allows us to select the patients who will be vaccinated.
00:18 It's a bit like the Identity Card of the military, like the blood groups.
00:21 It's called HLA-A2.
00:23 So, 45% of the population, at birth, genetically, is eligible for this vaccination.
00:28 Then, 50% of the patients who have responded to immunotherapy
00:32 will be able to enter a vaccination protocol,
00:35 which means that we are on about 7 to 10,000 patients per year in France.
00:38 If we expand to the European, American and Chinese scales,
00:42 we are on a little over 100,000 patients per year
00:45 who could receive this type of vaccination in the lung cancer.
00:49 [Music]
01:04 In 2023, we should have a breakthrough in cancer-fighting therapeutic vaccines.
01:10 Our Phase 3 results for patients with very advanced lung cancer.
01:13 We saw Moderna in December 2022 with a Phase 2.
01:16 We saw good results in preventing the tumor's receding
01:21 in lung cancer, melanoma, after surgery.
01:24 So, we are very preventive, and we combine it with other immunotherapies
01:29 to prevent patients from progressing and entering these heavy chemotherapy protocols.
01:34 [Music]